The clinical manifestations of acute and severe poisoning

Pramipexole, a dopamine receptor agonist with activity at both autoreceptors and postsynaptic receptors, has shown efficacy in aifimal models of parkinsonism. 

PRAMIPEXOLE DIHYDROCHLORIDE (Mirapex tablets 0.125 mg, tablets 0.25 mg, tablets 1 mg, tablets 1.5 mg) 

Pramipexole dihyrochloride is a non-ergot dopamine receptor agonist that stimulates dopamine receptors in the corpus striatum, relieving parkinsonian symptoms. It is used in the treatment of the signs and symptoms of idiopathic Parkinson s disease (PD). It may be used in conjunction with L-dopa. 

The hypolipidemic agent pravastatin differs from other HMG-CoA reductase inhibitors (e.g., lovastatin and simvastatin) because it has greater hydrophihcity as a result of the hydroxyl group attached to its decalin ring. The hydro-phihc nature of pravastatin accounts for its minimal penetration into the intracellular space of nonhepatic tissues, including an apparent inability to cross the blood-brain barrier. The drug is also well tolerated because it is rapidly absorbed and excreted, and does not accumulate in plasma even with repeated administration. 

Multiple well-controlled clinical trials have documented the efficacy and safety of simvastatin, pravastatin, lovastatin, and atorvastatin in reducing fatal and nonfatal CHD events, strokes, and total mortality. Rates of adverse events in statin trials were the same in the placebo groups and in the groups receiving the drug. This was true with regard to noncardiac illness and the two laboratory tests, hepatic transaminases and creatine kinase (CK), that are commonly monitored in patients taking statins. 

---